Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its gastrointestinal ("GI") ...

Using data from the Nurses’ Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS), Dr. Qiao-Li Wang and colleagues recently set out to further characterize the association between ...

DEM BioPharma, Inc. (DEM Bio), a biopharmaceutical company dedicated to discovering novel targets for solid tumors and ...

Precision oncology advancements have led to new treatment options for gastric cancer, including immunotherapy and targeted ...

Treatment for upper gastrointestinal (GI) cancers depends on several factors, including the type, location, and stage of the cancer (how far it has advanced). Treatments may include surgery, ...

In total, the researchers identified 8466 patients who were diagnosed with hiccups during the study period but before a potential cancer diagnosis. The vast majority (89%) were men. The incidence rate ...

Researchers shrink gastrointestinal tumors in mice using a yeast probiotic to deliver immunotherapy to the gut, offering a potentially novel strategy to target hard-to-reach gut cancers. Immunotherapy ...

GISTs originate from interstitial cells of Cajal and are staged by size, location, mitotic rate, and genetic mutations, influencing treatment strategies. Diagnosis involves imaging, endoscopy, biopsy, ...

Duodenal gastrointestinal stromal tumors (DGISTs) represent a rare subset of mesenchymal neoplasms of the gastrointestinal tract, accounting for approximately 3–5% of all gastrointestinal stromal ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — Seeking to build up its cancer business, GSK said Monday it is ...